Circulating tumour cells in bladder cancer patients treated with chemotherapy and radical cystectomy – enumeration, characterization and evaluation of prognostic value (the CIRCH-study)

CIRculating tumour cells in bladder cancer patients treated with CHemotherapy and radical cystectomy – enumeration, characterization and evaluation of prognostic value: a prospective investigational study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN72499664

Enrollment

182

Registered

2016-05-18

Start date

2016-03-17

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma Cancer

Interventions

Patients are recruited when treatment with chemotherapy either neoadjuvant as induction chemotherapy or in a palliative setting is considered. The levels of circulating tumour cells are monitored for,

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Locally advanced high grade urothelial carcinoma of the bladder scheduled for chemotherapy in the following settings; neoadjuvant, induction or palliative

Exclusion criteria

Exclusion criteria: Other malignant diseases

Design outcomes

Primary

Measure	Time frame
Dynamic change in CTC during chemotherapy, using the Cellsearch method	—

Secondary

Measure	Time frame
1. Progression Free Survival (PFS) from date of chemotherapy start to progression/death (via patient chart review, using clinical and radiological (RESIST 1.1) criteria.) 2. Overall Survival (OS), measured as death from any cause	—

Countries

Sweden

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026